 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway...

Petros Pharmaceuticals Provides Letter to Shareholders

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces...

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Petros Pharmaceuticals slips on $15M private placement financing

Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRANEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ('Petros' or 'the Company'), a pioneer in expanding consumer access to medication through the over...

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI Free Report)s stock price traded down 1.1% on Friday . The stock traded as low as $1.80 and last traded at $1.81. 8,840 shares changed hands during trading, a decline of 99% from the average session volume of 1,299,432 shares. The stock had previously closed...

Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 1.1%

Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? PR Newswire NEW YORK, April...

Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals?

Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ('Petros' or 'the Company') (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announced that it intends...

Petros Pharmaceuticals Announces Reverse Stock Split

Petros Pharmaceuticals (NASDAQ:PTPI  Get Rating) and Viking Therapeutics (NASDAQ:VKTX  Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, ...

Analyzing Petros Pharmaceuticals (NASDAQ:PTPI) and Viking Therapeutics (NASDAQ:VKTX)

Petros Pharmaceuticals ( NASDAQ:PTPI ) Third Quarter 2022 Results Key Financial Results Net loss: US$13.8m (loss...

Petros Pharmaceuticals Third Quarter 2022 Earnings: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences.LD Micro Main Event XV (Los...

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Watchers	6,215
52-Wk Low	$0.9172
52-Wk High	$9.54

Market Cap	$3.54M
Volume (M)	700.00
52-Wk High	$9.54
52-Wk Low	$0.9172

PTPI Petros Pharmaceuticals Inc

About

Feed

News

Fundamentals